Indivi acquires Cogitat to add brainwave AI to neurological drug research
The deal brings in NeuroRVQ and its developers. Indivi aims to spot subtle treatment effects, with experimental Alzheimer’s therapies an initial focus.
Loading page…
The deal brings in NeuroRVQ and its developers. Indivi aims to spot subtle treatment effects, with experimental Alzheimer’s therapies an initial focus.
Listen to this story
Indivi plans to use Cogitat’s EEG model, NeuroRVQ, alongside its smartphone-based movement and cognition assessments to detect treatment-related brain changes earlier in drug studies, including Alzheimer’s research. The acquisition adds a new measurement modality, but earlier detection remains a research goal, not a proven clinical outcome. The companies did not disclose the deal price, and their immediate priority is continuing to develop the model.
NeuroRVQ decodes EEG signals; Indivi says it preserves fast-changing details that other models may discard.
Cogitat’s model won first place in the Benchmarks for EEG Transfer Learning competition at NeurIPS, according to Startupticker.
Indivi’s existing tools measure movement and cognition via smartphones, and the company says they can help sponsors design smaller early-phase trials.
Swiss neurotechnology company Indivi has acquired Cogitat, adding an AI model for reading brainwave signals to its platform for measuring treatment response. The goal is to give drug developers earlier indications of whether experimental therapies are working, including treatments for Alzheimer’s disease. Financial terms were not disclosed.
Cogitat is an Imperial College London spin-out developing deep-learning models that decode cognitive function from EEG brain signals. Its model, NeuroRVQ, brings a brainwave-analysis capability to a buyer whose existing tools include smartphone assessments of movement and cognition. Indivi is headquartered in Basel, with offices in Córdoba, Spain, and Boston.
Indivi says it will work with Cogitat’s AI and scientific team to continue developing NeuroRVQ and apply it to detecting the effects of experimental Alzheimer’s treatments.
Indivi’s rationale centers on the gap between changes in brain activity and changes that become visible in memory or thinking. It sees EEG as a way to detect activity shifts before those problems are clinically apparent.
NeuroRVQ learns patterns in brain activity. According to Indivi, it preserves fine, fast-changing details that other models may discard. That is the intended research application, not an established clinical outcome.
Every brain is unique and speaks its own language. We’ve built an advanced AI model that works across every brain’s unique language without individual training to identify subtle changes in brain activity that have not been easily identifiable before.
Allan Ponniah, CEO and founder of Cogitat
Indivi already combines precision measurement, analytics and scientific expertise for biopharmaceutical sponsors. Its stated purpose is to help them design smaller early-phase trials and detect treatment effects with greater confidence.
Its existing disease work spans Parkinson’s, multiple sclerosis, Alzheimer’s and related dementias, as well as neuromuscular conditions including facioscapulohumeral muscular dystrophy.
Cogitat brings a machine-learning competition credential as well. Startupticker reports that its work won first place in the Benchmarks for EEG Transfer Learning competition at NeurIPS, ahead of academic and industry teams.
Indivi founder and CEO Guilhem Dupont places possible healthcare and consumer uses further out. The immediate priority is drug research: giving developers earlier information about how treatments affect the brain, while the combined teams continue developing the model.
Loading discussion...
Join the conversation
Explain where you see the greater value.
Be the first to share a perspective or an experience.
Reader comments
Newest comments first. Replies stay oldest first.